Barclays PLC Collegium Pharmaceutical, Inc Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

A detailed history of Barclays PLC transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Barclays PLC holds 75,052 shares of COLL stock, worth $2.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
75,052
Previous 75,052 -0.0%
Holding current value
$2.25 Million
Previous $2.9 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$31.4 - $39.07 $1.42 Million - $1.77 Million
45,291 Added 152.18%
75,052 $2.9 Million
Q2 2024

Aug 14, 2024
SELL
$31.36 - $39.99 $545,758 - $695,945
-17,403 Reduced 36.9%
29,761 $958,000
Q1 2024

May 15, 2024
SELL
$31.23 - $40.91 $798,488 - $1.05 Million
-25,568 Reduced 35.15%
47,164 $1.83 Million
Q4 2023

Feb 15, 2024
BUY
$21.16 - $30.8 $701,221 - $1.02 Million
33,139 Added 83.7%
72,732 $2.24 Million
Q3 2023

Nov 07, 2023
BUY
$21.23 - $24.28 $121,286 - $138,711
5,713 Added 16.86%
39,593 $886,000
Q2 2023

Aug 03, 2023
SELL
$21.06 - $24.0 $16,195 - $18,456
-769 Reduced 2.22%
33,880 $728,000
Q1 2023

May 04, 2023
BUY
$23.0 - $29.88 $101,821 - $132,278
4,427 Added 14.65%
34,649 $831,000
Q4 2022

Feb 13, 2023
BUY
$16.14 - $23.55 $62,720 - $91,515
3,886 Added 14.76%
30,222 $701,000
Q3 2022

Nov 03, 2022
SELL
$15.46 - $20.1 $232,008 - $301,640
-15,007 Reduced 36.3%
26,336 $423,000
Q2 2022

Aug 12, 2022
SELL
$14.22 - $20.88 $109,252 - $160,421
-7,683 Reduced 15.67%
41,343 $732,000
Q1 2022

May 16, 2022
SELL
$17.2 - $22.5 $405,318 - $530,212
-23,565 Reduced 32.46%
49,026 $998,000
Q4 2021

Feb 14, 2022
SELL
$17.5 - $21.35 $202,457 - $246,998
-11,569 Reduced 13.75%
72,591 $1.36 Million
Q3 2021

Nov 09, 2021
BUY
$17.75 - $25.39 $599,009 - $856,836
33,747 Added 66.94%
84,160 $1.66 Million
Q2 2021

Aug 13, 2021
SELL
$21.74 - $25.28 $504,998 - $587,229
-23,229 Reduced 31.54%
50,413 $1.19 Million
Q1 2021

May 13, 2021
BUY
$19.25 - $26.1 $1.2 Million - $1.63 Million
62,394 Added 554.71%
73,642 $1.75 Million
Q4 2020

Feb 11, 2021
SELL
$17.83 - $22.29 $81,073 - $101,352
-4,547 Reduced 28.79%
11,248 $225,000
Q3 2020

Nov 12, 2020
SELL
$15.78 - $20.82 $49,501 - $65,312
-3,137 Reduced 16.57%
15,795 $328,000
Q2 2020

Aug 12, 2020
BUY
$15.49 - $23.51 $124,771 - $189,373
8,055 Added 74.06%
18,932 $331,000
Q1 2020

May 13, 2020
SELL
$13.89 - $25.45 $295,634 - $541,677
-21,284 Reduced 66.18%
10,877 $178,000
Q4 2019

Feb 10, 2020
BUY
$10.7 - $22.24 $82,957 - $172,426
7,753 Added 31.76%
32,161 $662,000
Q3 2019

Nov 14, 2019
BUY
$10.16 - $13.28 $21,417 - $27,994
2,108 Added 9.45%
24,408 $280,000
Q2 2019

Aug 14, 2019
SELL
$10.62 - $16.59 $313,895 - $490,350
-29,557 Reduced 57.0%
22,300 $293,000
Q1 2019

May 15, 2019
BUY
$13.58 - $18.72 $192,157 - $264,888
14,150 Added 37.53%
51,857 $786,000
Q4 2018

Feb 14, 2019
BUY
$14.78 - $19.68 $394,448 - $525,219
26,688 Added 242.2%
37,707 $648,000
Q3 2018

Nov 14, 2018
BUY
$14.16 - $24.3 $66,679 - $114,428
4,709 Added 74.63%
11,019 $162,000
Q2 2018

Aug 14, 2018
SELL
$21.79 - $28.29 $96,900 - $125,805
-4,447 Reduced 41.34%
6,310 $150,000
Q1 2018

May 15, 2018
BUY
$18.15 - $29.21 $103,690 - $166,876
5,713 Added 113.26%
10,757 $276,000
Q4 2017

Feb 14, 2018
BUY
$9.3 - $19.14 $42,017 - $86,474
4,518 Added 858.94%
5,044 $93,000
Q3 2017

Nov 14, 2017
BUY
$9.15 - $11.97 $4,812 - $6,296
526
526 $6,000

Others Institutions Holding COLL

# of Institutions
255
Shares Held
38.6M
Call Options Held
100K
Put Options Held
21.1K
View Full List

About COLLEGIUM PHARMACEUTICAL, INC

COLL Quotes by TradingView
  • Ticker COLL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 34,126,200
  • Market Cap $1.02B
  • Description
  • Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...
More about COLL
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email